Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
This report presents the findings of a global survey on current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 physicians, who provided details of their treatments and prescribing practices.
[Full table of contents and product brochure]
With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.
Interventional treatments, such as peripheral nerve block and transcutaneous electrical nerve stimulation, are also used as physicians seek other approaches to treating NP. This background, the individual nature of NP and the drug (or drug combination) options used to treat patients, has created a complex therapeutic picture.
In a therapeutic field where treatments are often unsatisfactory, physicians seek to extent their understanding of NP in an effort to define needs and limitations. Knowledge in these areas is also important to drug developers, who seek a better understanding of patient needs and outcomes, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted an in-depth global survey on current treatments and drug prescribing practices, relating to NP. This survey involved the participation of more than 330 physicians and clinical centres in 56 countries.
Overview:
- Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
- In-depth information relevant to markets and opportunities in the NP field.
- 98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment.
- Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium.
- 74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin.
- Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients.
- Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available.
- A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS).
- An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions.
- Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP.
Table of Contents
Download Table of Contents as a PDF
Other users found this report page using the following search terms: tricyclic antidepressants SSRI SNRI anticonvulsants sodium channel blockers opioids NSAIDS cannabinoid Capsaicin diabetic neuropathy Diabetic neuropathic pain cin chemotherapy induced pain trigeminal neuralgia post-viral neuropathic pain neuropathic pain back pain complex regional pain syndrome pain neuropathic treatments treatment 2009 post neuropathicpaintreatmentsandprescribingpractices viral diabetic prescribingneuropathicpain
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.